The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

Fact checked by Nick Blackmer In a new study, semaglutide reduced liver fat, inflammation, and scarring in people with ...

As medications become increasingly popular to support weight loss, not all of them are approved by the U.S. Food and Drug ...

Ohio Attorney General Dave Yost sent letters to 14 medical spas warning them to stop making false or misleading claims about ...

Fatty liver disease, also called metabolic dysfunction-associated steatohepatitis (MASH), is a condition where fat ...

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

The risk for ocular problems linked to different formulations of semaglutide appear to vary, according to a new study, which ...

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...